Hims & Hers Health (HIMS) stock is trading sharply lower on May 12, 2026 after reporting Q1 results that missed both EPS and revenue estimates. The company posted a loss of $0.40 per share against a consensus estimate of $0.04, and revenue of $608M came in below the $617M Wall Street expected. Despite the headline miss, management raised full-year 2026 revenue guidance to $2.80B-$3.00B and guided Q2 revenue of $680M-$700M, both above prior consensus.

Key Drivers of the HIMS Stock Move
- Main Catalyst: Q1 earnings significantly missed estimates, with EPS missing by over 1,100%. The CFO cited write-downs on GLP-1 compounding ingredients and inventory, plus one-time M&A costs, as drivers of the outsized loss.
- Bull Case: Full-year revenue guidance was raised, Q2 guidance came in well above estimates, and subscribers grew 9% YoY to 2.58M. The CFO flagged record app downloads and traffic after the pivot to FDA-approved GLP-1s, and the company is projecting a return to profitability in 2027.
- Bear Case: The EPS miss was severe, and EBITDA guidance was cut by $25M. The transition away from compounded semaglutide introduces real near-term revenue and margin uncertainty. Bears will question whether the GLP-1 pivot is an opportunity or a signal of structural disruption.

The setup coming into earnings was already charged, with high short interest and retail enthusiasm fueling a pre-earnings run. The post-earnings selloff reflects the market’s discomfort with the profit profile, even as the top-line story remains intact. The core risk is execution: HIMS is navigating a regulatory-driven product shift in its highest-growth category at the same time it is absorbing M&A costs. Until the GLP-1 transition shows up cleanly in margins, the stock is likely to remain volatile.
HIMS Smart Money Activity
On the government side, Republican Rep. Tony Wied disclosed a purchase of $500K-$1M in HIMS in early February 2026, while the stock was trading lower, suggesting conviction at depressed levels. Insider activity has been dominated by scheduled sells from CFO Oluyemi Okupe, who has been steadily liquidating stock appreciation rights since January, totaling over $2.7M in disclosed sales through April. COO Michael Chi sold $2.4M worth on March 17. These insider sales appear to follow a programmatic schedule, though the consistent cadence across multiple executives is worth monitoring. On the positive side, the entire C-suite received large restricted stock awards in March, aligning long-term incentives with shareholders.

HIMS Unusual Options
Options flow heading into earnings was exceptionally active. On May 11, a single trader swept the Jan ’27 $40 Put repeatedly across more than a dozen tickets, accumulating over $2.1M in premium at the bid, a signal tagged as bullish (put selling or downside hedging into strength). Separately, a $330K sweep into Aug ’26 $40 Puts was tagged bearish. On the call side, a $212K sweep into Jan ’27 $42 Calls printed bullish. Post-earnings on May 12, flow shifted notably bearish, with large sweeps into Jun ’26 $25 Puts ($155K), $30 Puts ($164K), and the Jul ’26 $20 Put ($110K) all printing bearish or neutral. A $340K bullish sweep into the Aug ’26 $30 Call suggests some buyers are stepping in on the dip.

HIMS Analyst Focus
Upgrades/Confirmations:
- Needham (May 12) confirmed Buy, raised target from $30 to $35
- JP Morgan maintained Overweight, lowered target from $35 to $33
Notable Downgrades / Cautious Views:
- BTIG (Feb 24) downgraded to Hold; reconfirmed Hold today with no price target
- Citigroup confirmed Sell back in February with a $13.25 target; later upgraded to Hold in March at $24
- Bank of America upgraded from Sell to Hold in March; most recently at $32
Analyst Landscape: The analyst community is split. Needham and Barclays remain constructive (Buy, $35 and $29 respectively), JP Morgan is Overweight at $33, while multiple firms sit at Hold with targets ranging from $17 to $33. Citigroup had a Sell as recently as February. The median price target across recent ratings sits approximately in the $25-$29 range, suggesting the stock at current levels is trading near or at fair value by consensus.

HIMS Seasonality
Based on data since October 2019 (7 samples per month). May has historically shown a wide average gain (+15.5%) but only in 43% of years, reflecting a high-variance month. The data set is limited (7 samples max), so conclusions should be treated with caution. The upcoming June-July window has historically been the most consistent positive stretch, while August stands out as the weakest month of the year with an average decline of -14.6% and only 33% of periods positive.

HIMS Relative Performance
HIMS has dramatically improved its standing within its sector in 2026. It began the year in the bottom decile (below 10th percentile vs. same-sector peers), hit a nadir in late February, then staged a sharp recovery. By late April, it had climbed to the 40th percentile, and by May 11 (the day of earnings) had surged to the 50th percentile against same-sector peers on a trailing yearly basis. Today’s post-earnings drop will likely pull that reading back materially, though the recovery from the lows of February has been notable and suggests the stock was meaningfully outperforming into the event.